Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
Immuno-oncology
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers
The first Phase 3 win for an mRNA cancer therapy. Statistical significance was reported, effect size was not, and overall survival is still open.
Agilent Has Built an Annuity on Merck’s Clinical Programme, One Indication at a Time
Agilent won its eighth CE-marked companion diagnostic indication for a single PD-L1 assay, each one riding on a label expansion Merck paid to generate.